Hillstar Bio
United States
- Boston
- 02/04/2025
- Series A
- $67,000,000
Hillstar Bio is a precision immunology company based in Boston's Seaport neighborhood advancing a portfolio of programs against autoimmune diseases with unmet or underserved medical needs.
- Industry Biotechnology Research
- Website https://hillstarbio.com/
- LinkedIn https://www.linkedin.com/company/hillstar-bio/
Related People
Robert MabryFounder
United States -
Cambridge, Massachusetts
Biotechnology leader with extensive experience working across pharma, biotech, and venture- backed startups. Proven ability to lead cross-functional scientific and technology organizations in biologic discovery and development. Successful track record of driving innovative science and strategy to meet milestones from target discovery to IND yielding multiple biologic programs under clinical evaluation and one approval. Experience leading business development and in/out-licensing efforts, managing external collaborations, and building effective teams across multiple organizations.
Zell | $589,875 | (Apr 14, 2026)
Qoro | $750,000 | (Apr 14, 2026)
Remission Medical | Undisclosed Amount | (Apr 14, 2026)
Pixel Photonics | $5,880,875 | (Apr 14, 2026)
Critical Loop | $26,000,000 | (Apr 14, 2026)
AIRMO | $5,880,175 | (Apr 14, 2026)
Primepoint | $10,000,000 | (Apr 14, 2026)
Blocks | $6,000,000 | (Apr 14, 2026)
Slate Auto | $650,000,000 | (Apr 14, 2026)
Quartzy | $23,000,000 | (Apr 14, 2026)
Citra Space Corporation | $15,000,000 | (Apr 14, 2026)
Flashpass | $4,250,000 | (Apr 14, 2026)